Skip to content

Welcome to Discover Pharma! Today is : November 5, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Drug Discovery & Development

    Spot Biosystems reports early clinical evidence for non-viral dystrophin delivery in Duchenne muscular dystrophy

    Spot Biosystems has emerged from stealth with $40 million in [...]

    June 18, 2026
  • Advanced Therapies,Biotech & Pharma Business

    OrganaBio expands European access to perinatal and blood-derived research materials through Bio-Connect partnership

    OrganaBio has expanded access to its perinatal and peripheral blood-derived [...]

    June 18, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Genomics and sequencing,Pharmaceuticals and therapeutics,Therapeutic Areas

    Scribe Therapeutics secures $25M CIRM backing to advance CRISPR cardiometabolic therapies

    Scribe Therapeutics has secured more than $25 million in CIRM [...]

    June 18, 2026
  • Advanced Therapies,Opinion & Events

    AMM and SRT partner to expand ASCENT 2026 RNA therapeutics programme

    The Alliance for mRNA Medicines (AMM) and the Society for [...]

    June 18, 2026
  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    Resolution Therapeutics expands regenerative macrophage pipeline with in vivo mRNA programme

    Resolution Therapeutics has expanded its regenerative macrophage therapy pipeline with [...]

    June 18, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    CERo Therapeutics reports Phase 1 CER-1236 update with AML patient proceeding to stem cell transplant

    CERo Therapeutics Holdings, Inc has shared a Phase 1 update [...]

    June 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    Cellares secures $50M investment to expand automated cell therapy manufacturing

    Cellares has secured a $50 million growth equity investment from [...]

    June 16, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer

    Context Therapeutics has reported encouraging interim Phase 1 data for [...]

    June 15, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    VIVEbiotech expands in vivo lentiviral vector portfolio to 15 programmes

    VIVEbiotech has expanded its in vivo lentiviral vector portfolio to [...]

    June 15, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Vertex reports positive CASGEVY data in children and completes UK submission

    Vertex Pharmaceuticals has presented new Phase 3 data showing positive [...]

    June 11, 2026
Previous567Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • NICE recommends maralixibat for Alagille syndrome itching
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Mursla Bio validates liver-specific liquid biopsy platform
    Categories: Clinical & Regulatory, Genomics and sequencing, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • E2 secures FDA clearance for pulmonary embolism thrombectomy system
    Categories: Clinical & Regulatory, Medical devices
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top